Drug updates and approvals: 2018 in review

被引：5

作者：

Mospan, Cortney ^{[1
]}

Mospan, Geoffrey ^{[1
]}

Byland, Emily ^{[2
]}

Whitaker, William Blake ^{[3
]}

Xiong, Linda ^{[2
]}

Dunlap, Jordan ^{[2
]}

Canupp, Katherine ^{[2
]}

机构：

[1] Wingate Univ, Pharm, Levine Coll Hlth Sci, Wingate, NC 28174 USA

[2] Wingate Univ, Sch Pharm, Wingate, NC USA

[3] Wingate Univ, Sch Pharm, Hendersonville, NC USA

来源：

NURSE PRACTITIONER | 2018年 / 43卷 / 12期

关键词：

CF; cystic fibrosis; drug approvals; FDA; HIV; migraine; nausea and vomiting of pregnancy; new drugs; NVP; opioid withdrawal; plaque psoriasis;

D O I：

10.1097/01.NPR.0000547548.63764.6b

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

引用

页码：23 / 32

页数：10

共 33 条

[1]

[Anonymous], 2018, AIM ER AOOE PACK INS

[2]

[Anonymous], 2018, BONJ DOX SUCC PYR HY

[3]

[Anonymous], 2018, LUC LOF PACK INS

[4]

[Anonymous], 2018, IL TILDR ASMN PACK I

[5] Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II) [J].

Blumenfeld, Andrew M. ;

Bloudek, Lisa M. ;

Becker, Werner J. ;

Buse, Dawn C. ;

Varon, Sepideh F. ;

Maglinte, Gregory A. ;

Wilcox, Teresa K. ;

Kawata, Ariane K. ;

Lipton, Richard B. .

HEADACHE, 2013, 53 (04) :644-655

[6] The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies [J].

Burch, Rebecca C. ;

Loder, Stephen ;

Loder, Elizabeth ;

Smitherman, Todd A. .

HEADACHE, 2015, 55 (01) :21-34

[7]

Centers for Disease Control and Prevention, 2017, UND EP

[8]

Centers for Disease Control and Prevention, 2018, HIV SURV REP, V31

[9]

Centers for Disease Control and Prevention, 2018, HIV BAS

[10]

Committee on Practice Bulletins-Obstetrics, 2018, Obstet Gynecol, V131, pe15, DOI 10.1097/AOG.0000000000002456

← 1 2 3 4 →